Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: there is no intervention in this study.
- Who it may be relevant to
- Registry conditions: Coronary Artery Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Study ofPhoton Counting Computed Tomography in Acute Coronary Syndrom Patients
Overview
For patients with severe calcification or complex non-calcified plaques, we investigate wether PCCT can enable non-invasive, in vivo precise differentiation and quantitative measurement of plaque components (e.g., spotty calcification, necrotic core, fibrous tissue). Further we also study wether these quantitative imaging features can independently predict the risk of MACE in the short term and long term
Detailed description
Photon-counting detector CT (PCD-CT), as an innovative technology in the field of CT imaging, is gradually transforming the landscape of cardiac imaging. It differs significantly from conventional energy-integrating detector CT (EID-CT) in technical principles, bringing new possibilities for the diagnosis and assessment of heart diseases. This study will enrolled patients undergo standardized PCCT coronary angiography (CCTA) and make ultra-fine quantitative plaque analysis. Then at least 12 months of clinical follow-up will be performed. Finally correlation analysis between baseline plaque characteristics and follow-up endpoint events will be made.
Interventions
- Other there is no intervention in this study
there is no intervention
Primary outcome measures
- Major Adverse Cardiovascular Events, MACE [Time frame: 12months]
Eligibility criteria
Inclusion Criter:
- Adult patients (≥18 years) with clinically diagnosed coronary artery disease or undergoing CCTA for chest pain/heart failure symptoms.
- Able and willing to provide informed consent and complete scheduled follow-up visits.
Exclusion criteria
- History of iodine contrast agent allergy.
- Severe renal insufficiency (eGFR < 30 mL/min/1.73 m²).
- History of prior coronary artery bypass grafting (CABG).
- Pregnant or lactating women
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Chinese PLA General Hospital — Beijing
Identifiers
NCT: NCT07536607 · M2026-004-01